Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLCFan Zhang, Jie He, Wei Guo et al.|Journal of Thoracic Oncology|2022Cited by 74
Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancerBolun Zhou, Shugeng Gao, Fan Zhang et al.|Journal for ImmunoTherapy of Cancer|2024Cited by 8
Real-world long-term outcomes of non-small cell lung cancer patients undergoing neoadjuvant treatment with or without immune checkpoint inhibitorsBolun Zhou, Shugeng Gao, Lin Li et al.|Chinese Medical Journal|2025Cited by 3
Circulating tumor DNA as markers of dynamic recurrence risk and adjuvant chemotherapy benefit in resected non-small cell lung cancer.Wei Guo, Shugeng Gao, Fan Zhang et al.|Journal of Clinical Oncology|2021Cited by 2